FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114940128> ?p ?o ?g. }

• W2114940128 endingPage "2529" @default.
• W2114940128 startingPage "2523" @default.
• W2114940128 abstract "Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. In this two-part phase II study, the efficacy and safety of vandetanib was compared with that of gefitinib, an inhibitor of EGFR signaling.Patients (N = 168) with locally advanced or metastatic (stage IIIB/IV) non-small-cell lung cancer (NSCLC), after failure of first-line with or without second-line platinum-based chemotherapy, received once-daily vandetanib 300 mg (n = 83) or gefitinib 250 mg (n = 85) until disease progression or evidence of toxicity (part A). After a 4-week washout period, eligible patients had the option to switch to the alternative treatment (part B). Progression-free survival (PFS) was the primary efficacy assessment in part A, which was designed to have a higher than 75% power to detect a 33% prolongation of PFS at a one-sided significance level of .2.In part A, vandetanib prolonged PFS compared with gefitinib (hazard ratio = 0.69; 95% CI, 0.50 to 0.96; one-sided P = .013). Patients receiving vandetanib experienced adverse events that were manageable and generally consistent with inhibition of EGFR and VEGFR signaling, including diarrhea, rash, and hypertension. There were no unexpected safety findings with gefitinib. Overall survival, a secondary assessment, was not significantly different between patients initially randomly assigned to either vandetanib or gefitinib.The primary efficacy objective was achieved, with vandetanib demonstrating a significant prolongation of PFS versus gefitinib. Vandetanib 300 mg/d is currently being evaluated as a monotherapy in two randomized phase III studies in advanced NSCLC." @default.
• W2114940128 created "2016-06-24" @default.
• W2114940128 creator A5043549118 @default.
• W2114940128 creator A5055792960 @default.
• W2114940128 creator A5057370294 @default.
• W2114940128 creator A5066771958 @default.
• W2114940128 creator A5068824818 @default.
• W2114940128 creator A5071766547 @default.
• W2114940128 creator A5075327015 @default.
• W2114940128 creator A5075877134 @default.
• W2114940128 creator A5082501717 @default.
• W2114940128 creator A5084295219 @default.
• W2114940128 creator A5086651679 @default.
• W2114940128 date "2009-05-20" @default.
• W2114940128 modified "2023-09-27" @default.
• W2114940128 title "Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study" @default.
• W2114940128 cites W1787102412 @default.
• W2114940128 cites W1872420254 @default.
• W2114940128 cites W1965734230 @default.
• W2114940128 cites W1994567819 @default.
• W2114940128 cites W2037139573 @default.
• W2114940128 cites W2043696829 @default.
• W2114940128 cites W2062316437 @default.
• W2114940128 cites W2070767967 @default.
• W2114940128 cites W2090699402 @default.
• W2114940128 cites W2100785570 @default.
• W2114940128 cites W2111060860 @default.
• W2114940128 cites W2120718661 @default.
• W2114940128 cites W2122553809 @default.
• W2114940128 cites W2125212831 @default.
• W2114940128 cites W2138297714 @default.
• W2114940128 cites W2139236349 @default.
• W2114940128 cites W2145835533 @default.
• W2114940128 cites W2146404049 @default.
• W2114940128 cites W2147289344 @default.
• W2114940128 cites W2153477391 @default.
• W2114940128 cites W2153991063 @default.
• W2114940128 cites W2235706971 @default.
• W2114940128 cites W2469546081 @default.
• W2114940128 cites W2988080293 @default.
• W2114940128 doi "https://doi.org/10.1200/jco.2008.18.6015" @default.
• W2114940128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19332730" @default.
• W2114940128 hasPublicationYear "2009" @default.
• W2114940128 type Work @default.
• W2114940128 sameAs 2114940128 @default.
• W2114940128 citedByCount "191" @default.
• W2114940128 countsByYear W21149401282012 @default.
• W2114940128 countsByYear W21149401282013 @default.
• W2114940128 countsByYear W21149401282014 @default.
• W2114940128 countsByYear W21149401282015 @default.
• W2114940128 countsByYear W21149401282016 @default.
• W2114940128 countsByYear W21149401282017 @default.
• W2114940128 countsByYear W21149401282018 @default.
• W2114940128 countsByYear W21149401282020 @default.
• W2114940128 countsByYear W21149401282021 @default.
• W2114940128 countsByYear W21149401282023 @default.
• W2114940128 crossrefType "journal-article" @default.
• W2114940128 hasAuthorship W2114940128A5043549118 @default.
• W2114940128 hasAuthorship W2114940128A5055792960 @default.
• W2114940128 hasAuthorship W2114940128A5057370294 @default.
• W2114940128 hasAuthorship W2114940128A5066771958 @default.
• W2114940128 hasAuthorship W2114940128A5068824818 @default.
• W2114940128 hasAuthorship W2114940128A5071766547 @default.
• W2114940128 hasAuthorship W2114940128A5075327015 @default.
• W2114940128 hasAuthorship W2114940128A5075877134 @default.
• W2114940128 hasAuthorship W2114940128A5082501717 @default.
• W2114940128 hasAuthorship W2114940128A5084295219 @default.
• W2114940128 hasAuthorship W2114940128A5086651679 @default.
• W2114940128 hasBestOaLocation W21149401281 @default.
• W2114940128 hasConcept C121608353 @default.
• W2114940128 hasConcept C126322002 @default.
• W2114940128 hasConcept C143998085 @default.
• W2114940128 hasConcept C170493617 @default.
• W2114940128 hasConcept C197934379 @default.
• W2114940128 hasConcept C2776256026 @default.
• W2114940128 hasConcept C2777506169 @default.
• W2114940128 hasConcept C2778570526 @default.
• W2114940128 hasConcept C2779438470 @default.
• W2114940128 hasConcept C2780333294 @default.
• W2114940128 hasConcept C2780580887 @default.
• W2114940128 hasConcept C42362537 @default.
• W2114940128 hasConcept C71924100 @default.
• W2114940128 hasConcept C98274493 @default.
• W2114940128 hasConceptScore W2114940128C121608353 @default.
• W2114940128 hasConceptScore W2114940128C126322002 @default.
• W2114940128 hasConceptScore W2114940128C143998085 @default.
• W2114940128 hasConceptScore W2114940128C170493617 @default.
• W2114940128 hasConceptScore W2114940128C197934379 @default.
• W2114940128 hasConceptScore W2114940128C2776256026 @default.
• W2114940128 hasConceptScore W2114940128C2777506169 @default.
• W2114940128 hasConceptScore W2114940128C2778570526 @default.
• W2114940128 hasConceptScore W2114940128C2779438470 @default.
• W2114940128 hasConceptScore W2114940128C2780333294 @default.
• W2114940128 hasConceptScore W2114940128C2780580887 @default.
• W2114940128 hasConceptScore W2114940128C42362537 @default.
• W2114940128 hasConceptScore W2114940128C71924100 @default.
• W2114940128 hasConceptScore W2114940128C98274493 @default.
• W2114940128 hasIssue "15" @default.

• next